AVCT vs. 4BB, HVO, FUM, OXB, SCLP, FARN, BVXP, POLB, ETX, and TRX
Should you be buying Avacta Group stock or one of its competitors? The main competitors of Avacta Group include 4basebio (4BB), hVIVO (HVO), Futura Medical (FUM), Oxford Biomedica (OXB), Scancell (SCLP), Faron Pharmaceuticals Oy (FARN), Bioventix (BVXP), Poolbeg Pharma (POLB), e-therapeutics (ETX), and Tissue Regenix Group (TRX). These companies are all part of the "biotechnology" industry.
Avacta Group (LON:AVCT) and 4basebio (LON:4BB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk, community ranking and analyst recommendations.
In the previous week, Avacta Group had 2 more articles in the media than 4basebio. MarketBeat recorded 2 mentions for Avacta Group and 0 mentions for 4basebio. 4basebio's average media sentiment score of 0.00 beat Avacta Group's score of -0.14 indicating that 4basebio is being referred to more favorably in the news media.
4basebio has a net margin of 0.00% compared to Avacta Group's net margin of -267.00%. 4basebio's return on equity of -97.29% beat Avacta Group's return on equity.
4basebio has lower revenue, but higher earnings than Avacta Group. 4basebio is trading at a lower price-to-earnings ratio than Avacta Group, indicating that it is currently the more affordable of the two stocks.
Avacta Group has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500. Comparatively, 4basebio has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500.
8.8% of Avacta Group shares are held by institutional investors. Comparatively, 9.1% of 4basebio shares are held by institutional investors. 29.9% of Avacta Group shares are held by company insiders. Comparatively, 62.2% of 4basebio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Avacta Group received 212 more outperform votes than 4basebio when rated by MarketBeat users.
Summary
Avacta Group and 4basebio tied by winning 7 of the 14 factors compared between the two stocks.
Get Avacta Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVCT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AVCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avacta Group Competitors List
Related Companies and Tools
